Melissa Amber Burgess MD

Oncology•Pittsburgh, PA

Sarcoma

Assistant Professor of Medicine Division of Hematology/Oncology, Department of Medicine UPMC Hillman Cancer Center University of Pittsburgh School of Medicine

Join to View Full Profile

5115 Centre AvenueSecond FloorPittsburgh, PA 15232
Phone+1 412-692-4724
Fax+1 412-692-4705

Education & Training

UPMC Medical EducationFellowship, Hematology and Medical Oncology, 2012 - 2015
UPMC Medical EducationResidency, Internal Medicine, 2009 - 2012
Drexel University College of MedicineClass of 2009

Certifications & Licensure

PA State Medical License 2009 - 2026
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Clinical Trials

Study of Vorinostat in Combination With Gemcitabine and Docetaxel in Advanced Sarcoma Start of enrollment: 2013 Sep 24
Completed
Phase 1, Phase 2
A Study of Olaratumab (LY3012207) Plus Pembrolizumab in Participants With Advanced or Metastatic Soft Tissue Sarcoma Start of enrollment: 2017 Jul 03
COMPLETED
PHASE1
Safety and Efficacy of IMCnyeso in Advanced NY-ESO-1 and/or LAGE-1A Positive Cancers Start of enrollment: 2018 Jun 15
Terminated
Phase 1, Phase 2
A Study of AL102 in Patients With Progressing Desmoid Tumors Start of enrollment: 2021 Mar 30
ACTIVE_NOT_RECRUITING
PHASE2, PHASE3
Tazemetostat in Combination With Doxorubicin as Frontline Therapy for Advanced Epithelioid Sarcoma Start of enrollment: 2019 Dec 19
TERMINATED
PHASE3
Study of INBRX-109 in Conventional Chondrosarcoma Start of enrollment: 2021 Sep 23
RECRUITING
PHASE2
Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS) Start of enrollment: 2017 Aug 15
Active, not recruiting
Phase 3
A Study of HMPL-306 in Advanced Solid Tumors With IDH Mutations Start of enrollment: 2021 Feb 28
TERMINATED
PHASE1
CBT-1® in Combination With Doxorubicin in Patients With Metastatic, Unresectable Sarcomas Who Previously Progressed on Doxorubicin Start of enrollment: 2018 Mar 29
Recruiting
Phase 1
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

SARC028 Samples Reveal an Interplay between TGF-β, IFN Signaling, and Low HLA Class I Expression as Contributors to Ewing Sarcoma Checkpoint Blockade Resistance.
Jessica D Daley, Elina Mukherjee, David Ferraro, Shanthi Bhaskar, Anthony Green
Clinical Cancer Research. 2025-09-02
Phase II study of retifanlimab in patients with recurrent locally advanced or metastatic Merkel cell carcinoma (POD1UM-201).
Giovanni Grignani, Piotr Rutkowski, Céleste Lebbé, Michele Guida, Caroline Gaudy-Marqueste
Journal for Immunotherapy of Cancer. 2025-08-11
Malignant ossifying fibromyxoid tumour with TP53::PHF1 fusion: report of three cases suggesting an association between rare fusions and malignant phenotypes.
Nathaniel J Bigot, Azfar Neyaz, Ali Alani, Arivarasan Karunamurthy, Robert D Bubar
Histopathology. 2025-08-01

Lectures

Clinical activity of pembrolizumab (P) in undifferentiated pleomorphic sarcoma (UPS) and dedifferentiated/pleomorphic liposarcoma (LPS): Final results of SARC028 expan...
2019 ASCO Annual Meeting - 6/1/2019

Press Mentions

Pembrolizumab Makes Inroads in Sarcoma SubtypesNovember 14th, 2017
Pembrolizumab Antitumor Activity Promises Potential for Sarcoma SubtypesNovember 15th, 2016
Immunotherapy Effective Against Some Types of SarcomaJune 6th, 2016
Join now to see all

Committees

Committee Member/Medical Advisory Board Member, Pittsburgh Cure Sarcoma 2015 - Present

Professional Memberships

American Society of Clinical Oncology - ASCO
Member
Connective Tissue Oncology Society (CTOS)
Member
American Association for Cancer Research (AACR)
Member